<DOC>
	<DOCNO>NCT01451632</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability escalate dos MM-121 plus cetuximab MM-121 plus cetuximab plus irinotecan combination .</brief_summary>
	<brief_title>A Safety Study MM-121 With Cetuximab Irinotecan Patients With Advanced Cancers</brief_title>
	<detailed_description>This study Phase 1 pharmacologic dose-escalation trial MM-121 plus cetuximab plus irinotecan . The study assess safety , tolerability , pharmacokinetics MM-121 , cetuximab irinotecan .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>No standard option remain Adequate liver kidney function 18 year age History secondary active cancer last 3 year . Pregnant breast feed History severe allergic reaction contraindication cetuximab irinotecan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Metastatic Colorectal cancer</keyword>
	<keyword>Kras wild-type</keyword>
	<keyword>Squamous cell head neck cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>ErbB3</keyword>
	<keyword>MM-121</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Irinotecan</keyword>
</DOC>